Tasmar;治療藥物分析及市場預測 是由出版商GlobalData在2011年07月所出版的。
這份英文市場調查報告書包含Pages: 35 價格從美金2000起跳。
本報告提供帕金森氏症治療藥物的 Apokyn 的平台分析及市場預測，市場特徵為首，評估分析競爭，開發平台等，未來市場競爭等資訊，為您概述為以下內容。
1 目錄 1 目錄 2 簡介
- 2.1 帕金森氏症
- 2.2 症狀; 帕金森氏症
- 2.3 診斷; 帕金森氏症
- 2.4 帕金森氏症 治療策略
- 2.5 帕金森氏症 市場
- 2.6 免疫學
- 2.7 帕金森氏症, 年齡及性別
- 2.8 病因論
- 2.9 GlobalData 報告指南
3 帕金森氏症: 市場特性
- 3.1 帕金森氏症 市場
- 3.2 帕金森氏症 市場 預測及年複合成長率
- 3.3 影響因素; 帕金森氏症 市場
- 3.3.1 高患病率: 帕金森氏症是第二大最常見的神經退化性疾病
- 3.3.2 老年人口的增加
- 3.3.3 專利期間的結束; 潛力治療藥物
4 分期; 帕金森氏症和治療方法比較
- 4.1 Hoehn-Yahr 規模
- 4.2 修正 Hoehn-Yahr 規模
- 4.3 UPDRS;帕金森氏症統一規模
5 病期分類; 帕金森氏症
- 5.1 分佈; 帕金森氏症患者, 各年齡層
- 5.2 各階段患者分佈
6 Tasmar
- 6.1 簡介
- 6.2 作用機制
- 6.3 臨床研究
- 6.4 核准歷史記錄; Tasmar
- 6.5 銷售額的影響因素; Tasmar
- 6.5.1 風險; Tasmar引發致命急性的猛爆性肝衰竭的可能性
- 6.5.2美國以及EU的 Tasmar 銷售停止
- 6.5.3 專利期間的結束; Tasmar
- 6.5.4 日本未核准
- 6.6 醫藥品評估
- 6.6.1 藥物的風險·效益評估
- 6.6.2 競爭的激烈程度
- 6.7 銷售額預期
- 6.7.1 目標患者群; Tasmar
- 6.7.2 投藥
- 6.7.3 市場滲透率
- 6.7.4 治療的年度成本
- 6.7.5 銷售額預期; Tasmar
7 帕金森氏症 市場: 附錄
- 7.1 市場定義
- 7.2 簡稱一覽
- 7.3 調查方法
- 7.3.1 調查範圍
- 7.3.2 二級研究
- 7.3.3 預測
- 7.3.4 服用這種藥物的患者數
- 7.3.5 治療藥物的淨市場滲透率
- 7.3.6 年度淨用藥量
- 7.3.7 治療的年度成本
- 7.3.8 主要研究
- 7.3.9 專家委員會
- 7.4 治療藥物的銷售額預期模式
- 7.5 諮詢方式
- 7.6 免責聲明
- 7.7 資訊來源
1.1 表格一覽
- 表格 1: 臨床進行性及非進行性症狀; 帕金森氏症
- 表格 2: 帕金森氏症的 Hoehn - Yahr 重症階段
- 表格 3: 帕金森氏症的 Hoehn - Yahr 重症階段
- 表格 4: UPDRS 其1，第4項
- 表格 5: UPDRS 其2，第13項
- 表格 6: UPDRS 其3，第14項
- 表格 7: UPDRS 其3，第14項
- 表格 8: Hoehn - Yahr 分類的帕金森氏症患者的分佈
- 表格 9: 結果; 第三階段 美國/加拿大 波動調查
- 表格 10: 結果; 第三階段 歐洲 波動調查
- 表格 11: 結果; 第三階段 美國/加拿大的 非波動調查
- 表格 12: 核准歷史記錄; Tasmar
- 表格 13: 藥物的風險·效益評估
- 表格 14: 不利事件概要
- 表格 15: 有效性比較; Tasmar
- 表格 16: 服用數量; Tasmar
- 表格 17: 治療的年度成本; Tasmar
- 表格 18: Tasmar, 帕金森氏症, 全球市場, 銷售額預期 ($m)
- 表格 19: Tasmar, 帕金森氏症, 美國, 銷售額預期 ($m)
- 表格 20: Tasmar, 帕金森氏症, 英國, 銷售額預期 ($m)
- 表格 21: Tasmar, 帕金森氏症, 法國, 銷售額預期 ($m)
- 表格 22: Tasmar, 帕金森氏症, 德國, 銷售額預期 ($m)
- 表格 23: Tasmar, 帕金森氏症, 義大利, 銷售額預期 ($m)
- 表格 24: Tasmar, 帕金森氏症, 西班牙, 銷售額預期 ($m)
1.2 圖表一覽
- 圖 1: 最新的藥物療法; 帕金森氏症以及潛在的作用部位 - CNS(中樞神經系統)
- 圖 2: 各年齡患病率; 帕金森氏症 - 歐洲5個國家的老年人
- 圖 3: 帕金森氏症, 全球市場, 市場規模預測 ($bn)
- 圖 4: 60歲以上人口的比例, 全球, 1950-2050
- 圖 5: UPDRS的分佈點
- 圖 6: Hoehn - Yahr 分類的帕金森氏症患者的分佈
- 圖 7: 藥物模式圖; Tasmar
- 圖 8: Tasmar, 帕金森氏症, 全球市場, 銷售額預期 ($m)
- 圖 9: Tasmar, 帕金森氏症, 美國, 銷售額預期 ($m)
- 圖 10: Tasmar, 帕金森氏症, 英國, 銷售額預期 ($m)
- 圖 11: Tasmar, 帕金森氏症, 法國, 銷售額預期 ($m)
- 圖 12: Tasmar, 帕金森氏症, 德國, 銷售額預期 ($m)
- 圖 13: Tasmar, 帕金森氏症, 義大利, 銷售額預期 ($m)
- 圖 14: Tasmar, 帕金森氏症, 西班牙, 銷售額預期 ($m)
- 圖 15: Tasmar, 帕金森氏症, 全球市場, 銷售額分佈 各國 (%)
- 圖 16: 藥物模式圖
- 圖 17: 服用這種藥物的患者
Abstract
Summary
GlobalData's pharmaceuticals report, "Tasmar - Analysis and Estimates from 2004 to 2020" provides Tasmarsales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2004-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Tasmar including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Tasmar including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2004-2020 for Tasmar in the US and EU5
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of contents
1. Table of contents
- 1.1 List of Tables
- 1.2 List of Figures
2. Introduction
- 2.1 Parkinson's Disease
- 2.2 Symptoms of Parkinson's Disease
- 2.3 Diagnosis of Parkinson's Disease
- 2.4 Parkinson's Disease Treatment Strategies
- 2.5 Parkinson's Disease Market
- 2.6 Epidemiology
- 2.7 Parkinson's Disease by Age and Gender
- 2.8 Etiology
- 2.9 GlobalData Report Guidance
3. Parkinson's Disease: Market Characterization
- 3.1 Parkinson's Disease Market
- 3.2 Parkinson's Disease Market Forecasts and CAGR
- 3.3 Factors Affecting Parkinson's Disease Market
- 3.3.1 High Prevalence: Parkinson's Disease is the Second Most Frequent Neurodegenerative Disorder
- 3.3.2 Increase in Old Age Population
- 3.3.3 Patent Expiry of Prominent Drugs
4. Stages of Parkinson's Disease and Comparison of Treatments
- 4.1 The Hoehn and Yahr Scale
- 4.2 Modified Hoehn and Yahr Scale
- 4.3 The UPDRS
5. Staging of Parkinson's Disease
- 5.1 Distribution of Parkinson's Disease Patients by Age Groups
- 5.2 Distribution of Patients by Stages
6. Tasmar
- 6.1 Introduction
- 6.2 Mechanism of Action
- 6.3 Clinical Studies
- 6.4 Approval History of Tasmar
- 6.5 Factors Affecting Sales of Tasmar
- 6.5.1 Risk of Potentially Fatal, Acute Fulminant Liver Failure with Tasmar
- 6.5.2 Suspension of Tasmar from the US and EU
- 6.5.3 Patent Expiry of Tasmar
- 6.5.4 Tasmar Not Approved in Japan
- 6.6 Drug Evaluation
- 6.6.1 Drug Risk Benefit Score
- 6.6.2 Intensity of Competition
- 6.7 Sales Estimates
- 6.7.1 Target Patient Pool for Tasmar
- 6.7.2 Dosing
- 6.7.3 Market Penetration
- 6.7.4 Annual Cost of Therapy
- 6.7.5 Sales Estimates of Tasmar
7. Parkinson Disease Market: Appendix
- 7.1 Market Definitions
- 7.2 List of Abberiviations
- 7.3 Research Methodology
- 7.3.1 Coverage
- 7.3.2 Secondary Research
- 7.3.3 Forecasting
- 7.3.4 Number of Patients Approved to take the Drug
- 7.3.5 Net Penetration of Drug
- 7.3.6 Net Annual Dosing
- 7.3.7 Annual Cost of Therapy
- 7.3.8 Primary Research
- 7.3.9 Expert Panels
- 7.4 Drug Sales Estimates Model
- 7.5 Contact Us
- 7.6 Disclaimer
- 7.7 Sources
List of Tables
- Table 1: Clinical Motor and Nonmotor Features of Parkinson's Disease
- Table 2: Hoehn and Yahr Stages of Parkinson's Disease
- Table 3: Hoehn and Yahr Stages of Parkinson's Disease
- Table 4: Four Items, Part 1 of UPDRS
- Table 5: Thirteen Items, Part 2 of UPDRS
- Table 6: Fourteen Items, Part 3 of UPDRS
- Table 7: Fourteen Items, Part 3 of UPDRS
- Table 8: Distribution of Parkinson's Patients According to Hoehn and Yahr Classification
- Table 9: Results of Phase III US/Canada Fluctuation Study
- Table 10: Results of Phase III European Fluctuation Study
- Table 11: Results of Phase III US/Canadian Non-Fluctuation Study
- Table 12: Approval History of Tasmar
- Table 13: Drug Risk Benefit Score
- Table 14: Summary of Adverse Events
- Table 15: Efficacy Comparison of Tasmar
- Table 16: Dosing Details of Tasmar
- Table 17: Annual Cost of Therapy of Tasmar, 2010
- Table 18: Tasmar, Parkinson's Disease, Global, Sales Estimates ($m), 2004-2020
- Table 19: Tasmar, Parkinson's Disease, The US, Sales Estimates ($m), 2004-2020
- Table 20: Tasmar, Parkinson's Disease, The UK, Sales Estimates ($m), 2005-2020
- Table 21: Tasmar, Parkinson's Disease, France, Sales Estimates ($m), 2005-2020
- Table 22: Tasmar, Parkinson's Disease, Germany, Sales Estimates ($m), 2005-2020
- Table 23: Tasmar, Parkinson's Disease, Italy, Sales Estimates ($m), 2005-2020
- Table 24: Tasmar, Parkinson's Disease, Spain, Sales Estimates ($m), 2005-2020
List of Figures
- Figure 1: Current Pharmacologic Therapies for Parkinson's Disease and Their Potential Sites of Action in the CNS
- Figure 2: The Age-Specific Prevalence Rates of Parkinson's Disease in the Elderly Among Five European Countries, 2003
- Figure 3: Parkinson's Disease, Global, Market Size Estimates ($bn), 2010-2020
- Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050
- Figure 5: Points Distribution of UPDRS
- Figure 6: Distribution of Parkinson's Disease Patients by Hoehn & Yahr Classification
- Figure 7: Drug Model Diagram of Tasmar
- Figure 8: Tasmar, Parkinson's Disease, Global, Sales Estimates ($m), 2004-2020
- Figure 9: Tasmar, Parkinson's Disease, The US, Sales Estimates ($m), 2004-2020
- Figure 10: Tasmar, Parkinson's Disease, The UK, Sales Estimates ($m), 2005-2020
- Figure 11: Tasmar, Parkinson's Disease, France, Sales Estimates ($m), 2005-2020
- Figure 12: Tasmar, Parkinson's Disease, Germany, Sales Estimates ($m), 2005-2020
- Figure 13: Tasmar, Parkinson's Disease, Italy, Sales Estimates ($m), 2005-2020
- Figure 14: Tasmar, Parkinson's Disease, Spain, Sales Estimates ($m), 2005-2020
- Figure 15: Tasmar, Parkinson's Disease, Global, Sales Distribution by Country (%), 2011
- Figure 16: Drug Model Diagram
- Figure 17: Patients Approved for the Drug
|
